Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection
© Mohapatra et al; licensee BioMed Central Ltd. 2010
Received: 10 April 2009
Accepted: 18 January 2010
Published: 18 January 2010
It has been shown previously that administration of Francisella tularensis (Ft) Live Vaccine Strain (LVS) lipopolysaccharide (LPS) protects mice against subsequent challenge with Ft LVS and blunts the pro-inflammatory cytokine response.
To further investigate the molecular mechanisms that underlie Ft LVS LPS-mediated protection, we profiled global hepatic gene expression following Ft LVS LPS or saline pre-treatment and subsequent Ft LVS challenge using Affymetrix arrays.
A large number of genes (> 3,000) were differentially expressed at 48 hours post-infection. The degree of modulation of inflammatory genes by infection was clearly attenuated by pre-treatment with Ft LVS LPS in the surviving mice. However, Ft LVS LPS alone had a subtle effect on the gene expression profile of the uninfected mice. By employing gene set enrichment analysis, we discovered significant up-regulation of the fatty acid metabolism pathway, which is regulated by peroxisome proliferator activated receptors (PPARs).
We hypothesize that the LPS-induced blunting of pro-inflammatory response in mouse is, in part, mediated by PPARs (α and γ).
Tularemia is caused by the Gram-negative, non-motile, intracellular coccobacillus, Francisella tularensis (Ft), so named after Tulare county of California where the disease was initially identified . Rodents, along with rabbits and hares, are the chief hosts of the bacterium. It is transmitted to humans mostly by insect bites, handling of animal carcasses, and ingestion or inhalation. Symptoms of tularemia typically appear 3 to 5 days after initial contact with the pathogen and include sudden fever, chills, headaches, diarrhea, muscle aches, joint pain, dry cough and progressive weakness; however, the symptoms and the severity of illness, are highly dependent upon the dose and route of inoculation . The number of cases of tularemia has steadily declined in the United States since 1950; between 1990 and 2000, only 1,368 cases of tularemia were reported to the Centers for Disease Control and Prevention (CDC) with an annual average of approximately 120 cases until 2003 . The CDC has classified Ft as a Category A agent due to its low infectious dose, easy dissemination by the aerosol route, and potential to cause severe morbidity and mortality. Ft has been used previously as a biological weapon . Furthermore, during the cold war, both the United States and the former Soviet Union stockpiled Ft for use as a potential biological weapon [2, 5].
An attenuated "Live Vaccine Strain" (LVS), developed in the former Soviet Union by repeated passage of Ft subspecies holarctica on agar plates and subsequently through mice , has been used to vaccinate humans. While vaccination with Ft LVS provides significant protection against more highly virulent strains [7–9], the strain has not been licensed for general public use in the United States due to the fact that the molecular basis for the attenuation is presently unknown . Nonetheless, Ft LVS is virulent in mice by many routes and causes an infection that resembles human tularemia .
Infection of mice with Ft results in a marked inflammatory response that has been suggested to be responsible for most of the tissue damage associated with human tularemia [11, 12]. Mice challenged i.p. with Ft LVS display the highest bacterial burden in the liver when compared to spleen and lung . Interaction of Ft with cells of the innate immune system (macrophages, dendritic cells, neutrophils, NK cells) initiates a cascade of cytokine production including IFN-γ, TNF-α leading to production of reactive nitrogen and oxygen species . In the liver, increased bacterial burden is accompanied by increased hepatic mRNA synthesis of the pro-inflammatory genes TNF-α, IFN-γ, KC, MCP-1, and iNOS. A later wave of gene expression is associated with the development of "alternatively activated" macrophages that facilitates increased intracellular replication of Ft and, ultimately, death .
LPS, an integral structural component of the outer membrane of all Gram-negative bacteria, is often a primary mediator of host inflammatory sequelae induced by Gram-negative bacterial infection. Unlike enterobacterial LPS, previous studies have shown that Ft LVS LPS is weakly endotoxic and a poor Toll-like receptor (TLR) 4 agonist . Despite its lack of endotoxic properties, mice pre-treated with Ft LVS LPS two days prior to lethal Ft LVS challenge are protected and display decreased bacterial burden as well as a reduced inflammatory response . This previous work assessed changes in gene expression using real-time PCR and, therefore, a relatively small subset of inflammatory genes was analyzed. To gain insights into the mechanism(s) of Ft LPS-mediated protection of mice from death caused by Ft LVS, we profiled hepatic transcriptome (using Affymetrix expression arrays) of Ft-infected mice with or without LPS-pre-treatment.
Female C57BL/6J mice were obtained from Jackson Labs in Bar Harbor, ME. 48 hours prior to Ft LVS challenge, mice were injected i.p. with either 100 ng of Ft LVS LPS or an equivalent volume of saline. On the day of challenge, 3 saline- and 3 Ft LVS LPS-pre-treated animals were sacrificed (uninfected controls), while all remaining mice were challenged i.p. with ~4-5 × 105 Ft LVS. Ft LVS-challenged mice were sacrificed (in groups of 3) at 24 and 48 hours post-infection. This entire experiment was performed 3 times. Within each individual experiment, equal amounts of extracted RNA from biological replicate samples were pooled. Pooled RNA from separate experiments was used as biological replicates. All experimental procedures were approved by the Institutional Animal Care and Use Committee and met or exceeded requirements of the Public Health Service/National Institutes of Health and the Animal Welfare Act.
Whole liver was collected from mice and preserved in RNAlater® (Applied Biosystems/Ambion Foster City, CA). After homogenization, total RNA was extracted and purified using the RNAeasy system according to manufacturer's instructions (Qiagen Valencia, CA). The QIAGEN RNase-free DNase supplement kit was used to ensure that the RNA was free from DNA contamination. All RNA samples were checked for both quality and quantity as described previously [17, 18].
Real Time PCR
Real-time PCR was performed in a Sequence Detector System (ABI Prism 7900 Sequence Detection System and software; Applied Biosystems, Foster City, CA) as described previously . Levels of mRNA for specific murine genes were reported as relative gene expression over background levels detected in control samples. Primers were designed using the Primer Express™ Program (Applied Biosystems, Foster City, CA) in conjunction with GenBank with the following sequences.
B-cell leukemia/lymphoma 6 forward: GTCAGAGTATTCGGATTCTAGCTGTG
B-cell leukemia/lymphoma 6 reverse: GCAGCGTGTGCCTCTTGAG
Traf 2 binding protein (TIFA) forward: GGCCACTGGAAGACTCTCAGG
Traf 2 binding protein (TIFA) reverse: GGATGGTAAATGGTCATCTGGAG
cytochrome P450, family 2, subfamily b, polypeptide 10 (Cyp2b10) forward: CAGACACCATAAGGGAGGCTCT
cytochrome P450, family 2, subfamily b, polypeptide 10 (Cyp2b10) reverse: GATCACACCATATTCCTTGAAGGTT
Heat shock protein 1B (Hspa1b) forward: GCACGGCGTGTGAGAGG
Heat shock protein 1B (Hspa1b) reverse: TGATGGATGTGTAGAAGTCGATGC.
RNA was processed and labelled according to the standard target labelling protocols and the samples were hybridized, stained, and scanned per standard Affymetrix protocols at VBI core laboratory on Mouse 430 2.0 expression arrays (Affymetrix Inc., Santa Clara, CA). This platform consists of 45,101 probe sets representing 21,309 genes of the mouse genome.
Microarray data analysis
Data input and subsequent steps were performed using the Bioconductor package "affy"  in R statistical environment - Version 2.8.1 . Raw microarray data obtained from CEL files were pre-processed by the gcRMA algorithm (GC Robust Multiarray Average)  that performs the three steps: (i) adjustment of the gene expression signal against the background caused by optical noise and non-specific binding, (ii) robust multi-array normalization , and (iii) summarization of the probes belonging to each probe set.
The probe sets were further selected in an unbiased manner by removing those associated with a very low degree of variability (inter-quartile range less than 0.5) across all the samples. This reduced the number of probe sets from 45,101 to 19,535. Statistical analysis was performed using the software package "limma"  by applying a linear model to the expression measurement (log intensities) for each gene. For each comparison of interest, the genes were assigned p-values after controlling for false discovery rate . For assessment of differential expression, the empirical Bayes method was applied . A cut-off of p < 0.05 and > = 2-fold change was used as the criterion for whether or not a gene was significantly modulated by a treatment. All the significantly modulated genes in any of the pair wise comparison of interest are listed in Additional file 1. The microarray data (both raw and normalized) have been submitted at the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/, Data set: GSE16207).
Gene set enrichment analysis (GSEA)
where the t-statistic is a measure of the individual differential expression for each gene in the pathway. While each individual t-statistic represents the gene-level difference between two groups (treated versus control), the pathway score represents the pathway-level difference between the two groups. Calculation of the pathway score was performed using the bioconductor package GSEABase . GSEA has earlier been shown to detect differential regulation of pathways when gene-level changes are very small or undetectable [32, 33] and hence was considered appropriate for the present context. The pathway observed to be most significantly modulated was confirmed by permutation testing with the gseattperm function in the package Category . The pathway scores are listed in Additional file 2.
Comparison of differential gene expression due to LPS treatment
Each of the values d0, d1, and d2 refers to the difference of the average gene expression of 3 samples. The average and variation of these numbers were compared against a normal distribution and tested if the mean was significantly different from zero. For PPARα and γ (but not β/δ), the effect was found to be statistically significant (p < 0.05).
Comparison of differential gene expressions due to LPS treatment and infection on fatty acid metabolism
For each gene, it refers to the difference of the gene expression values averaged over 3 samples. The average and variation of these numbers (Dp and Di) were compared against a normal distribution and tested if the mean was significantly different from zero. For each case (LPS or infection), the average differences of Dp and Di were tested against normal distribution found to be significantly different from zero (p < 0.01).
Alteration in gene expression after infection
We discovered 3,515 genes to be differentially expressed after 48 hours of infection. These include Bcl proteins 3, 6, and 10; heat shock proteins 1, 1A, 1B, and 90; genes induced by interferons; interleukin 1β; and LPS binding protein and tumor necrosis factor. For easier data visualization, a shorter list of 79 of these genes (with >40-fold change) is presented in the heat map in Additional file 3 A. Genes with modified expression fell into two categories based on whether they were up or down-regulated by infection. The up-regulated genes include interferon γ (IFN-γ) as well as chemokine (C-X-C motif) ligands IP-10 (Cxcl10), KC (Cxcl1), and MCP-1 (Ccl2). This is consistent with our previously published results on up-regulation of pro-inflammatory cytokines by mouse liver upon Ft LVS infection . The genes that were down-regulated at 48 hours post-infection include carbonic anhydrase 3 and guanidinoacetate methyltransferase, both of which are known to be down-regulated in response to liver injury [35, 36].
The time course for gene expression for up- and down-regulated genes was examined separately. Box plots were drawn for each group of genes across the three time points: uninfected, 24 hours, and 48 hours post-infection (Additional file 3B, C). For each post-infection time point, saline- and LPS-pre-treated mice were juxtaposed. Two trends are visible in these box plots. First, with time, infection progressively alters the level of gene expression (red-colored boxes). This is true for both up- and down-regulated genes. Secondly, LPS-pre-treatment (green boxes) opposes the transcriptional changes caused by Ft LVS infection at both 24 hours and 48 hours post-infection, thus keeping the gene expression level less deviated from uninfected state. Effect of LPS-pre-treatment was found to be statistically significant (p < 0.01) for both up- and down-regulated genes.
We discovered a total of 34 genes to be differentially expressed compared to uninfected control. These included chemokine ligand IP-10 and genes controlled by pro-inflammatory cytokines TNF-α, IL-1β, IFN-γ; namely, interferon regulatory factor 1, Cd274 antigen, metallothionein 2, proteasome subunit (Psmb9), and tumor necrosis factor Tnfsf10 were progressively up-regulated after infection. Similar to the trend seen for the other group, up-regulation of these genes at 24 hours post-infection was lessened by LPS-pre-treatment.
In addition to the effects on the specific genes, LPS-pre-treatment had a substantial influence on the number of genes differentially expressed due to infection. A total of 3,515 genes were found to be differentially expressed in mice without LPS-pre-treatment, but only 1,494 genes with LPS-pre-treatment after 48 hours post-infection as compared to the uninfected controls (0 hr post-infection). For more than 99% of the latter list of genes (1,483 out of 1,494) the N-fold was in the same direction as that in mice without LPS-pre-treatment. Furthermore, for 1,100 of these 1,483 genes, the magnitude of change was smaller in the LPS pre-treated mice, suggesting LPS had a general blunting effect on infection-induced gene expression profile.
Validation of select genes
LPS-induced changes in pathways
PPARs belong to the superfamily of nuclear hormone receptors with three known isoforms, α,β or δ, and γ, that differ in their tissue distribution and functional activity . While PPARβ/δ is ubiquitous, PPARγ is expressed in adipocytes, T- and B-cells, monocytes/macrophages, dendritic cells, and epithelial cells [38, 39].
Ft LVS infection of mice is associated with profound changes in the levels of pro-inflammatory cytokines whose expression is decreased by pre-treatment with 100 ng of Ft LVS LPS. After 48 hours post-infection, LPS-treated mice exhibit significantly reduced hepatic gene expression  (Fig. 2), circulating cytokine levels  and increased survival . We previously postulated that pre-treating the mice with LPS accomplishes the following results: (i) dampened bacterial growth, (ii) suppressed pro-inflammatory response, and (iii) induction of a late Ag-specific protective adaptive immune response . It was recently shown that the latter is due to the induction of Ft LVS LPS-specific antibodies by a subset of B1a cells . Upon global profiling of hepatic gene expression, we discovered a number of genes that were differentially expressed, especially at 48 hours post-infection, a time at which many of these changes were counteracted by prior LPS treatment. The effect of LPS treatment was less evident at 24 hours post-infection or at day 0 (without infection). Since it is clear that LPS protects the mice from death by Ft LVS, we made the reasonable assumption that the protective molecular changes were already in motion 48 hours after LPS treatment (day 0) and we sought to discover the gene expression signature of those LPS-induced changes. Using "Gene set enrichment analysis" that explores coordinated changes in functionally related genes, we discovered that the KEGG pathway "Fatty acid metabolism" was up-regulated at 48 hours post-infection. Further investigation pointed to simultaneous up-regulation of PPARα and γ by LPS-pre-treatment (Fig. 5).
Many of the genes in the "Fatty acid metabolism" pathway are transcriptionally controlled by peroxisome proliferator-activated receptors (PPARs). PPARs (α, β/δ and γ) are master regulators of energy homeostasis. They are nuclear receptors that upon activation by specific ligands bind to specific response elements near the promoter of their target genes. In this way, PPARs sense the lipid concentration and composition in the cellular environment [43, 44]. In fact, PPARs are the receptors for endogenous lipid molecules such as prostaglandins or hydroxy-containing PUFA such as 12/15-hydroxyeicosatetraenoic (HETE), 13-hydroxyoctadecadienoic (HODE), and dietary compounds such as conjugated linoleic acid. PPARα and γ were originally identified as the molecular target for the fibrate class of lipid-lowering drugs or the thiazolidinedione (TZD) class of antidiabetic drugs, respectively. Our results show that the down-regulation of the proinflammatory cytokine and chemokine response induced by LPS pre-treatment is paralleled by increased expression of PPARα and γ. In the liver, PPARα is mainly expressed by hepatocytes, where it regulates oxidation of free fatty acids. Its ligands include unsaturated fatty acids and eicosanoids derived from arachidonic and linoleic acids. We show that LPS-pre-treatment resulted in up-regulation of the enzymes involved in fatty acid oxidation (Fig. 5), which suggests a higher degree of PPARα activation by endogenous ligands.
Both PPARα and γ are expressed in Kupffer cells, a specialized subset of macrophages that reside in the hepatic sinusoids . Other immune cells present in the liver such as dendritic cells or T cells also express PPARγ. In addition to its role in lipid metabolism, PPARα and γ have long been recognized for their influence on inflammatory pathways  mostly by repression of pro-inflammatory gene expression. More recently, it has been shown that liver PPARα controls acute phase response (APR) via a liver-specific attenuation of pro-inflammatory cytokine gene expression . In this model, PPARα modulates both TNF-α/IL-1 and IL-6 signaling through a direct action on the pathway or via the down-regulation of IL-1-mediated stimulation of IL-6 expression. This model is consistent with our finding of up-regulated PPARα-responsive genes and reduced levels of pro-inflammatory cytokine gene expression and protein levels. Interestingly, while purified Ft LPS causes an up-regulation of PPARs and their responsive genes, infection with the whole bacterium causes down-regulation of the same genes (Fig. 5). These findings are in line with a recent report demonstrating that E. coli LPS up-regulated PPARγ expression in the immune system of pigs by inducing the generation of endogenous PPARγ agonists such as 15d PGJ (2) . Thus, while enterobacterial and Ft LPS differ in molecular targets (i.e., TLR4 versus TLR2, respectively) and their ability to induce inflammatory cytokines, both types of LPS may induce the generation of endogenous PPAR agonists as a mechanism of down-regulating inflammation.
PPARγ has been recently shown to be a key molecular switch in the induction of alternatively activated macrophages . Moreover, it has been shown that infection of macrophages with Ft LVS induced alternative activation with up-regulation of the signature genes arginase I, FIZZI, and macrophage mannose receptor . Interestingly, the cytokines IL-4 and IL-13 drive differentiation into alternatively activated macrophages through IL-4Rα and STAT6 signaling,  and in addition, IL-4 treatment of macrophages up-regulates PPARγ and PPARγ responsive genes . While alternatively activated macrophages display an anti-inflammatory phenotype, which might dampen Ft LVS-induced inflammation, they are unable to kill intracellular pathogens. In this regard, Ft LVS induced alternatively activated macrophages through production of IL-4 and IL-13, which resulted in enhanced intracellular bacterial survival and replication. On the other hand, the inability of macrophages to become alternatively activated in IL-4Rα or STAT6-deficient mice leads to a more prolonged IL-12 response when compared to WT littermates . Thus, the role of PPARγ in the immunopathogenesis of tularemia should be interpreted with caution as it might have both beneficial and detrimental effects in the outcome of the disease. The induction of the PPAR-controlled pathway in our data is consistent with transcriptional profiling results of F. tularensis infection of human peripheral blood mononuclear cells (PBMC) .
In summary, we have examined the gene expression of the mouse liver before and after infection with Ft LVS, with or without LPS-pre-treatment, and demonstrated that, in accordance with previous results from our laboratory, LPS causes significant attenuation of gene-expression changes after infection with Ft LVS. Additionally, we demonstrate for the first time that Ft LPS causes subtle changes in hepatic gene expression after 48 hours of treatment in uninfected mice. By using gene set enrichment analysis (GSEA) we showed that many genes involved in fatty acid metabolism are up-regulated in a coordinated manner along with up-regulation of the nuclear factor PPARα (and to a lesser extent PPARγ). We suggest that LPS-induced attenuation of pro-inflammatory response to Ft LVS is partly mediated through hepatic PPARα and γ, possibly through the induction of alternatively activated macrophages. These findings are in line with numerous reports on the anti-inflammatory efficacy of PPARs. Future studies aimed at examining the effect of Ft LVS or type A strains on the hepatic and pulmonary pathology following cell-specific deletion of PPARα or γ from immune cells are needed to further dissect the role of PPARs in the pathogenesis and prevention of tularemia.
The authors thank Lisa Gunderman for help in proof reading and formatting the manuscript. This project was funded through National Institutes of Health Cooperative Agreement number 1 U54 Al057168-01 to S. Vogel and O. Crasta through subcontract from the University of Maryland, Baltimore, M. Levine, PI and through Collaborative Research Team funding from the Virginia Bioinformatics Institute to O. Crasta.
- Sjostedt A: Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007, 1105: 1-29. 10.1196/annals.1409.009.View ArticlePubMedGoogle Scholar
- Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, et al: Tularemia as a biological weapon: medical and public health management. JAMA. 2001, 285 (21): 2763-2773. 10.1001/jama.285.21.2763.View ArticlePubMedGoogle Scholar
- Summary of Notifiable Diseases --- United States. 2003, [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5254a1.htm]
- Harris S: Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci. 1992, 666: 21-52. 10.1111/j.1749-6632.1992.tb38021.x.View ArticlePubMedGoogle Scholar
- Vogel G: Infectious diseases. An obscure weapon of the cold war edges into the limelight. Science. 2003, 302 (5643): 222-223. 10.1126/science.302.5643.222.View ArticlePubMedGoogle Scholar
- Eigelsbach HT, Downs CM: Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961, 87: 415-425.PubMedGoogle Scholar
- Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S: Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961, 107: 702-714.View ArticlePubMedGoogle Scholar
- Hornick R: Tularemia revisited. N Engl J Med. 2001, 345 (22): 1637-1639. 10.1056/NEJM200111293452211.View ArticlePubMedGoogle Scholar
- Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S: Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961, 107: 689-701.View ArticlePubMedGoogle Scholar
- Titball RW, Petrosino JF: Francisella tularensis genomics and proteomics. Ann N Y Acad Sci. 2007, 1105: 98-121. 10.1196/annals.1409.015.View ArticlePubMedGoogle Scholar
- Elkins KL, Cowley SC, Bosio CM: Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 2003, 5 (2): 135-142. 10.1016/S1286-4579(02)00084-9.View ArticlePubMedGoogle Scholar
- Ellis J, Oyston PC, Green M, Titball RW: Tularemia. Clin Microbiol Rev. 2002, 15 (4): 631-646. 10.1128/CMR.15.4.631-646.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ, Rallabhandi P, Cuesta N, Vogel SN: Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol. 2006, 176 (11): 6888-6899.View ArticlePubMedGoogle Scholar
- Elkins KL, Cowley SC, Bosio CM: Innate and adaptive immunity to Francisella. Ann N Y Acad Sci. 2007, 1105: 284-324. 10.1196/annals.1409.014.View ArticlePubMedGoogle Scholar
- Shirey KA, Cole LE, Keegan AD, Vogel SN: Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. Journal of Immunology. 2008, 181 (6): 4159-4167.View ArticleGoogle Scholar
- Gunn JS, Ernst RK: The structure and function of Francisella lipopolysaccharide. Ann N Y Acad Sci. 2007, 1105: 202-218. 10.1196/annals.1409.006.View ArticlePubMedPubMed CentralGoogle Scholar
- Djavani MM, Crasta OR, Zapata JC, Fei Z, Folkerts O, Sobral B, Swindells M, Bryant J, Davis H, Pauza CD, et al: Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol. 2007, 81 (15): 7960-7973. 10.1128/JVI.00536-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, Hasday JD, Mohapatra SK, Crasta OR, Vogel SN, et al: An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proc Natl Acad Sci USA. 2008, 105 (52): 20816-20821. 10.1073/pnas.0807265105.View ArticlePubMedPubMed CentralGoogle Scholar
- Cuesta N, Salkowski CA, Thomas KE, Vogel SN: Regulation of lipopolysaccharide sensitivity by IFN regulatory factor-2. J Immunol. 2003, 170 (11): 5739-5747.View ArticlePubMedGoogle Scholar
- Gautier L, Cope L, Bolstad BM, Irizarry RA: affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004, 20 (3): 307-315. 10.1093/bioinformatics/btg405.View ArticlePubMedGoogle Scholar
- R_Development_Core_Team: R: A Language and Environment for Statistical Computing. 2008Google Scholar
- Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association. 2004, 99 (468): 909-917. 10.1198/016214504000000683.View ArticleGoogle Scholar
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4 (2): 249-264. 10.1093/biostatistics/4.2.249.View ArticlePubMedGoogle Scholar
- Smyth GK: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Edited by: R Gentleman VC, Dudoit S, Irizarry R, Huber W. 2005, New York: Springer, 397-420. full_text.View ArticleGoogle Scholar
- Benjamini Y, Hochberg Y: Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological. 1995, 57 (1): 289-300.Google Scholar
- Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3-PubMedGoogle Scholar
- Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, et al: KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008, D480-484. 36 Database
- Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28 (1): 27-30. 10.1093/nar/28.1.27.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006, D354-357. 10.1093/nar/gkj102. 34 Database
- Gentleman R, Morgan M, Huber W: Gene set enrichment analysis. Bioconductor Case Studies. Edited by: F Hahne WH, Gentleman R, Falcon S. 2008, New york: SpringerGoogle Scholar
- Morgan M, Falcon S, Gentleman R: GSEABase: Gene set enrichment data structures and methods. R package version 1.2.2. 2008Google Scholar
- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003, 34 (3): 267-273. 10.1038/ng1180.View ArticlePubMedGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102 (43): 15545-15550. 10.1073/pnas.0506580102.View ArticlePubMedPubMed CentralGoogle Scholar
- Gentleman R, Falcon S, Sarkar D: Category: Category Analysis. R package version 2.8.3 edn. 2008Google Scholar
- Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stuhlet K, Graf J, Roeb E: Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics. 2006, 6 (24): 6538-6548. 10.1002/pmic.200600580.View ArticlePubMedGoogle Scholar
- Schnackenberg LK, Chen M, Sun J, Holland RD, Dragan Y, Tong W, Welsh W, Beger RD: Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol Appl Pharmacol. 2009, 235 (1): 25-32. 10.1016/j.taap.2008.11.015.View ArticlePubMedGoogle Scholar
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: the second decade. Cell. 1995, 83 (6): 835-839. 10.1016/0092-8674(95)90199-X.View ArticlePubMedGoogle Scholar
- Spiegelman BM: PPARgamma in monocytes: less pain, any gain?. Cell. 1998, 93 (2): 153-155. 10.1016/S0092-8674(00)81567-6.View ArticlePubMedGoogle Scholar
- Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun. 1996, 222 (3): 844-851. 10.1006/bbrc.1996.0832.View ArticlePubMedGoogle Scholar
- Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG: Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 2000, 21 (4): 823-826. 10.1093/carcin/21.4.823.View ArticlePubMedGoogle Scholar
- Mandard S, Muller M, Kersten S: Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004, 61 (4): 393-416. 10.1007/s00018-003-3216-3.View ArticlePubMedGoogle Scholar
- Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Herzenberg LA, Vogel SN: Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci USA. 2009, 106 (11): 4343-4348. 10.1073/pnas.0813411106.View ArticlePubMedPubMed CentralGoogle Scholar
- Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med. 2004, 10 (4): 355-361. 10.1038/nm1025.View ArticlePubMedGoogle Scholar
- Grimaldi PA: Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell Mol Life Sci. 2007, 64 (19-20): 2459-2464. 10.1007/s00018-007-7278-5.View ArticlePubMedGoogle Scholar
- Crispe IN: The liver as a lymphoid organ. Annu Rev Immunol. 2009, 27: 147-163. 10.1146/annurev.immunol.021908.132629.View ArticlePubMedGoogle Scholar
- Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28 (12): 551-558. 10.1016/j.it.2007.09.003.View ArticlePubMedGoogle Scholar
- Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996, 384 (6604): 39-43. 10.1038/384039a0.View ArticlePubMedGoogle Scholar
- Mansouri RM, Bauge E, Staels B, Gervois P: Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology. 2008, 149 (6): 3215-3223. 10.1210/en.2007-1339.View ArticlePubMedGoogle Scholar
- Liu Y, Lu J, Shi J, Hou Y, Zhu H, Zhao S, Liu H, Ding B, Yin Y, Yi G: Increased expression of the peroxisome proliferator-activated receptor gamma in the immune system of weaned pigs after Escherichia coli lipopolysaccharide injection. Vet Immunol Immunopathol. 2008, 124 (1-2): 82-92. 10.1016/j.vetimm.2008.02.014.View ArticlePubMedGoogle Scholar
- Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Eagle AR, Vats D, Brombacher F, Ferrante AW, et al: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007, 447 (7148): 1116-1120. 10.1038/nature05894.View ArticlePubMedPubMed CentralGoogle Scholar
- Martinez FO, Helming L, Gordon S: Alternative Activation of Macrophages: An Immunologic Functional Perspective. Annu Rev Immunol. 2009, 27: 451-83. 10.1146/annurev.immunol.021908.132532.View ArticlePubMedGoogle Scholar
- Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK: Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 1999, 400 (6742): 378-382. 10.1038/22572.View ArticlePubMedGoogle Scholar
- Paranavitana C, Pittman PR, Velauthapillai M, Zelazowska E, DaSilva L: Transcriptional profiling of Francisella tularensis infected peripheral blood mononuclear cells: a predictive tool for tularemia. Fems Immunology and Medical Microbiology. 2008, 54 (1): 92-103. 10.1111/j.1574-695X.2008.00456.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/10/10/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.